Skip to main content
  • About ELGA
    • About ELGA
    • Ultrapure Water
    • Purification Technologies
    • Impurities In Water
    • Guides & White Papers
    • Approved Partners
    • ELGA's History
    • Sustainability
    • Careers
    • Events
  • Blog
    • Analytical Chemistry
    • Clinical & Pharma
    • Cool Science
    • Environment and sustainability
    • Life in the lab
    • Purelab product design
    • Science of the future
    • Water Purity
    • Water in the lab
  • Contact
  • Language
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Other Veolia Sites
    • Veolia
    • Veolia Fondation
    • Veolia Water Technologies
Home ELGA LabWater
  • Products
  • Applications
  • Case Studies
  • Support
  • Products
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • ELGA Full Product Range
  • Applications
  • Case Studies
    • Unlocking the secrets of the Antarctic with the aid of ultrapure water
    • Abbott Diagnostics chooses ELGA MEDICA systems in South Asia
    • Ca’Foscari University- A New Method for Investigating Environmental Tracers in Ice
    • Ca’Foscari University- Investigating Contaminants in Antarctic Ice
    • DASA: The biggest medical diagnostics company in Brazil
    • ELGA helps immuneserology labs maximize uptime
    • Importance of ultrapure Type 1+ water for the development of generic medicines
    • MEDICA® Pro selected for Siemens ADVIA® analyzers at City General Hospital
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® flex: an ideal training system for today's research method
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Zentrale Reinstwasser-Aufbereitung für Analyser
  • Support
    • Support & Services
    • Laboratory Planning
    • Register a Product
    • Register Your Product (USA & Canada Only)
  • Products
    • PURELAB
      • PURELAB Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB Chorus 2+
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® flex 1 & 2
      • PURELAB® flex 3 & 4
    • CENTRA
      • CENTRA® 60/120
      • CENTRA® RDS
      • CENTRA® R200
    • MEDICA
      • MEDICA® 7/15
      • MEDICA® EDI 15/30
      • MEDICA® Pro EDI 60/120
      • MEDICA® Pro-LPS
      • MEDICA® Pro-R and Pro-RE
      • MEDICA® R200
    • BIOPURE
      • BIOPURE 7/15
      • BIOPURE 60/120
      • BIOPURE 200/300/600
    • ELGA Full Product Range
      • PURELAB® Classic
  • Applications
  • Case Studies
    • Unlocking the secrets of the Antarctic with the aid of ultrapure water
    • Abbott Diagnostics chooses ELGA MEDICA systems in South Asia
    • Ca’Foscari University- A New Method for Investigating Environmental Tracers in Ice
    • Ca’Foscari University- Investigating Contaminants in Antarctic Ice
    • DASA: The biggest medical diagnostics company in Brazil
    • ELGA helps immuneserology labs maximize uptime
    • Importance of ultrapure Type 1+ water for the development of generic medicines
    • MEDICA® Pro selected for Siemens ADVIA® analyzers at City General Hospital
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® flex: an ideal training system for today's research method
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Zentrale Reinstwasser-Aufbereitung für Analyser
  • Support
    • Support & Services
    • Laboratory Planning
    • Register a Product
    • Register Your Product (USA & Canada Only)
  • Language
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Other Veolia Sites
    • Veolia
    • Veolia Fondation
    • Veolia Water Technologies
  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Sitemap
  • Impressum

Let's talk about lab water

  • Categories
    • Analytical Chemistry
    • Clinical & Pharma
    • Cool Science
    • Environment & Sustainability
    • Future Science
    • Life in The Lab
    • PURELAB Product Design
    • Science of the Future
    • Water In The Lab
    • Water Purity
  • Authors
    • ELGA Editorial Team
    • Natasha Zarach
    • Dr Paul Whitehead
    • Dr Alison Halliday
    • John Walker
Science of the Future
Clinical & Pharma

Developing Nanoemulsions for Treating Neurodegenerative Diseases

24 Jul 2019
- by Dr Alison Halliday

Brain Scan images

A new study successfully demonstrates the feasibility and therapeutic potential of a new nanoformulation as an effective drug delivery tool to the brain.

Neurodegenerative disorders, including Parkinson’s and Alzheimer’s, are characterised by neuronal death in specific regions of the brain accompanied by deposits of aggregated proteins. With no cures, new treatments are desperately needed that can slow down or stop the progression of these devastating diseases.

To identify new therapeutic targets, researchers are untangling the complex web of pathways involved in disease development – and they are uncovering increasing evidence to suspect a central role for tiny organelles called lysosomes. Packed full of enzymes, these are involved in many everyday cell functions – but it is problems with their role in clearing misfolded and accumulated proteins that are implicated in neurodegenerative disease. As the acidic pH of lysosomes is often perturbed in neurodegenerative disorders, developing ways to correct this could potentially restore normal function.

Restoring the pH Balance of Lysosomes using Acidic Nanoparticles

PLGA1 nanoparticles have recently emerged as a promising carrier for delivery and sustained release of therapeutic agents – due to their biocompatibility, and their ability to protect their cargo from degradation, increasing its half-life. But exploiting the acidic nature of PLGA by using it not only as the carrier but also as the active compound, offers an attractive potential therapeutic opportunity to correct lysosomal dysfunction in neurodegenerative disease.

In previous studies, researchers have shown that acidic nanoparticles (aNPs) of PLGA can restore the function of defective lysosomes – and slow down Parkinson’s disease-related neurodegeneration. But despite these promising initial results, the delivery of aNPs remains challenging and their diffusion is mostly limited to the site of injection directly into the brain.

Developing Nanoemulsions with Improved Brain Delivery and Diffusion 

Developing new formulations that can be delivered by systemic injection into the bloodstream and cross the blood-brain-barrier (BBB) offers a much less invasive route for delivering therapeutics into the brain. Nanoemulsions – dispersions of tiny droplets consisting of oil, surfactant and water – are novel drug delivery systems. Along with improved stability and high loading capacity, they offer additional advantages for carrying hydrophobic agents into the brain – providing extra protection for their load and a natural tendency to cross the BBB.

Promising Initial Results

In a new study, a team of researchers designed an acidic nanoemulsion loaded with PLGA with the aim of enhancing brain diffusion and achieving brain drug delivery after systemic injection.2 The researchers prepared nanoemulsion-based therapies loaded with PLGA and a red fluorescent dye to enable tracking inside the brain – using ultrapure water prepared using an ELGA PURELAB® laboratory water purification system.They carried out a series of experiments showing that these acidic nanoemulsions could restore the acidic lysosomal pH in cellular models of Parkinson’s disease – and directly injecting it into the brain of mice leads to widespread diffusion and internalisation into lysosomes. Finally, they demonstrated that a fraction of their nanoformulation successfully crosses the BBB after systemic delivery and reaches lysosomes in brain cells.

This successful demonstration of the ability of nanoemulsions to cross the BBB, although low in number, suggests this strategy could be highly promising for future drug delivery to the brain. Further nanotechnology-based development will focus on improving the sustained release of PLGA, offering the possibility for future effective new therapies for neurodegenerative diseases.

Why choose ELGA LabWater?

Our history of innovation helps us to research new water purification technologies and techniques. ELGA has been a trusted name in pure and ultrapure water since 1937. We help you to achieve consistent, accurate results. 

 

References

1.  Poly(DL-lactide-co-glycolide)
2.  Prévot et al. Harnessing lysosomal pH through PLGA nanoemulsion as a treatment of lysosomal-related neurodegenerative diseases. Bioconjugate Chemistry 2018      
     doi: 10.1021/acs.bioconjchem.8b00697

 

Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

You may also be interested in...

24 Nov 2019
Clinical & Pharma, Science of the Future
Using ‘Molecular Bar Codes’ To Tackle The Problem Of Counterfeit Drugs
Dr Alison Halliday

pills

pills
18 Nov 2019
Cool Science, Science of the Future
Extracting Bioactive Compounds from Pomegranate Peel
Dr Alison Halliday

pomegranate

Pomegranate

Highlights

8 Dec 2019
Research into Silver Nanoparticles
1 Dec 2019
Screening Formulations for New 3D Printed Wound Healing Materials
24 Nov 2019
Using ‘Molecular Bar Codes’ To Tackle The Problem Of Counterfeit Drugs
18 Nov 2019
Extracting Bioactive Compounds from Pomegranate Peel
30 Apr 2019
An Ultra-Sensitive New DNA Sensor for Detecting and Diagnosing Genetic Diseases
30 Apr 2019
Developing a New Diagnostic Test for an Aggressive Childhood Cancer
30 Apr 2019
New Synthetic Cannabinoid Discovered in ‘e-liquids’ for Clectronic Cigarettes
30 Apr 2019
Using hair samples to monitor exposure to alternative plasticisers

Categories

  • Analytical Chemistry
  • Clinical & Pharma
  • Cool Science
  • Environment & Sustainability
  • Future Science
  • Life in The Lab
  • PURELAB Product Design
  • Science of the Future
  • Water In The Lab
  • Water Purity

Video

  • Contact Us
  • Get a Quote
  • Book a Demo
  • Find an Approved Partner

Contact Us

At ELGA LabWater, we have exciting offers and news about our lab water purification products that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy here.

ELGA Labwater works with a network of Approved Partners. In order to answer your questions or inquiries, we may pass your contact details to an Approved Partner, who may contact you directly. You can find a list of our Approved Business Partners here.

If you would like to receive updates from ELGA and our Approved partners please tick the box below:

YES I'd like to receive updates from ELGA LabWater & Approved Partners based on my details

Get a Quote

At ELGA LabWater, we have exciting offers and news about our lab water purification products that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy here.

ELGA Labwater works with a network of Approved Partners. In order to answer your questions or inquiries, we may pass your contact details to an Approved Partner, who may contact you directly. You can find a list of our Approved Business Partners here.

If you would like to receive updates from ELGA and our Approved partners please tick the box below:

YES I'd like to receive updates from ELGA LabWater & Approved Partners based on my details

Book a Demo

At ELGA LabWater, we have exciting offers and news about our lab water purification products that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy here.

ELGA Labwater works with a network of Approved Partners. In order to answer your questions or inquiries, we may pass your contact details to an Approved Partner, who may contact you directly. You can find a list of our Approved Business Partners here.

If you would like to receive updates from ELGA and our Approved partners please tick the box below:

YES I'd like to receive updates from ELGA LabWater & Approved Partners based on my details

ELGA LabWater Head Quarters

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
T: +44 (0) 203 567 7300
F: +44 (0) 203 567 7205

The Ultrapure Water Specialists

  • Company History
  • Support & Services
  • Events

Case Studies

  • Abbott Diagnostics
  • DASA Medical Diagnostics
  • NeoDIN Medical Institute
  • North Staffordshire NHS Trust
  • Olsberg Vocational College

Resources

  • Learn About Ultrapure Water
  • Guides and White Papers
  • Purification Technologies
  • Applications
  • Impurities In Water

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • Language
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Other Veolia Sites
    • Veolia
    • Veolia Fondation
    • Veolia Water Technologies

© VWS (UK) Ltd. trading as ELGA LabWater. 2019 - All rights reserved.
ELGA is the global laboratory water brand name of Veolia.

  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Sitemap
  • Impressum
Elga Veolia
TOP

© 2017 ELGA Veolia